17.98
0.26 (1.47%)
| Previous Close | 17.72 |
| Open | 17.98 |
| Volume | 1,134,552 |
| Avg. Volume (3M) | 1,499,540 |
| Market Cap | 1,934,845,696 |
| Price / Sales | 2.87 |
| Price / Book | 4.40 |
| 52 Weeks Range | |
| Earnings Date | 2 May 2024 |
| Profit Margin | -30.67% |
| Operating Margin (TTM) | -22.35% |
| Diluted EPS (TTM) | -1.58 |
| Quarterly Revenue Growth (YOY) | 19.30% |
| Total Debt/Equity (MRQ) | 186.65% |
| Current Ratio (MRQ) | 6.46 |
| Operating Cash Flow (TTM) | -67.17 M |
| Levered Free Cash Flow (TTM) | -24.58 M |
| Return on Assets (TTM) | -9.30% |
| Return on Equity (TTM) | -43.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | NovoCure Limited | Bearish | Bearish |
Stockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 9.23% |
| % Held by Institutions | 86.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Wells Fargo, 122.47%) | Buy |
| Median | 24.00 (33.48%) | |
| Low | 18.00 (Evercore ISI Group, 0.11%) | Hold |
| Average | 27.33 (52.00%) | |
| Total | 1 Buy, 2 Hold | |
| Avg. Price @ Call | 17.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 01 Oct 2024 | 18.00 (0.11%) | Hold | 14.89 |
| HC Wainwright & Co. | 26 Jul 2024 | 24.00 (33.48%) | Hold | 19.02 |
| Wells Fargo | 26 Jul 2024 | 40.00 (122.47%) | Buy | 19.02 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Oct 2024 | Announcement | Novocure to Report Third Quarter 2024 Financial Results |
| 09 Sep 2024 | Announcement | Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy |
| 03 Sep 2024 | Announcement | Novocure Announces Planned CEO Transition |
| 28 Aug 2024 | Announcement | Novocure to Participate in 2024 Wells Fargo Healthcare Conference |
| 14 Aug 2024 | Announcement | Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer |
| 25 Jul 2024 | Announcement | Novocure Reports Second Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |